Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $1.0 million.

  • Collegium Pharmaceutical's Depreciation & Amortization (CF) rose 919.66% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 1424.02%. This contributed to the annual value of $3.9 million for FY2024, which is 1029.75% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Depreciation & Amortization (CF) stood at $1.0 million for Q3 2025, which was up 919.66% from $1.1 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Depreciation & Amortization (CF) high stood at $1.1 million for Q2 2025, and its period low was $424000.0 during Q4 2021.
  • In the last 5 years, Collegium Pharmaceutical's Depreciation & Amortization (CF) had a median value of $835000.0 in 2023 and averaged $791105.3.
  • Per our database at Business Quant, Collegium Pharmaceutical's Depreciation & Amortization (CF) skyrocketed by 12974.36% in 2021 and then skyrocketed by 636.87% in 2024.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Depreciation & Amortization (CF) stood at $424000.0 in 2021, then soared by 94.58% to $825000.0 in 2022, then grew by 15.03% to $949000.0 in 2023, then grew by 9.69% to $1.0 million in 2024, then fell by 0.77% to $1.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.0 million in Q3 2025, compared to $1.1 million in Q2 2025 and $1.1 million in Q1 2025.